Pulmonary Hypertension
Conditions
Brief summary
Recruit at least 700 PH patients, follow up every 6 months based on a computerized follow-up system. Primary outcomes are adverse drug events and all-cause death.
Interventions
None listed
Sponsors
China National Center for Cardiovascular Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
3 Months to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age from 3 months to 85 years, no sex preference; * Right heart catheter meet the following conditions simultaneously: mPAP≥25mmHg, and PVR \> 3 Wood units(in children PVRi \> 3 WU x m2), and PAWP≤15 mmHg at rest; * Patients diagnosed with group 1,2,4,5 PH according to the WHO classification, detailed description is as follows: Pulmonary arterial hypertension, Lung disease / chronic hypoxia associated pulmonary hypertension, Pulmonary hypertension associated with pulmonary artery stenosis / obstruction and Pulmonary hypertension caused by other multiple factors * Take at least one pulmonary hypertension targeted drug or calcium antagonist; * Signed written informed consent.
Exclusion criteria
* Patients diagnosed with pulmonary hypertension related to left heart disease;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse drug events | through study completion, an average of 6 months |
| All-cause Mortality | through study completion, an average of 6 months |
Countries
China
Contacts
Primary ContactTingting Guo, M.D
Outcome results
None listed